2023-10-29 16:00Financial Performance - The company's revenue for Q3 2023 reached ¥2,920,138,789.43, representing a year-on-year increase of 5.49%[4] - The net profit attributable to shareholders for Q3 2023 was ¥352,944,967.45, a decrease of 6.05% compared to the same period last year[4] - The adjusted net profit attributable to shareholders under non-IFRS was ¥480,583,101.41, down 6.82% year-on-year[4] - Total revenue for the period reached ¥8,560,256,911.27, an increase of 15.6% compared to ¥7,402,793,998.96 in the previous period[26] - The net profit for Q3 2023 was CNY 1,134,523,142.41, an increase of 20.2% compared to CNY 944,178,254.54 in Q3 2022[27] - The company reported a total comprehensive income of CNY 1,107,456,956.68 for Q3 2023, compared to CNY 899,030,529.31 in Q3 2022, marking a growth of 23.2%[28] - Basic earnings per share for Q3 2023 were CNY 0.6430, up from CNY 0.5412 in the same period last year, representing an increase of 18.8%[28] Revenue Sources - Revenue from the top 20 global pharmaceutical companies amounted to approximately ¥124,923.91 million, a year-on-year increase of 5.44%[10] - Revenue from overseas laboratories and factories grew by 26.70% year-on-year, accounting for 13.34% of total revenue[9] - Revenue from clinical research services reached ¥1,262,099,160.97, marking a year-on-year increase of 28.48%[8] Cash Flow and Assets - The company reported a net cash flow from operating activities of ¥2,029,402,975.72, reflecting a significant increase of 45.47% year-to-date[4] - Cash and cash equivalents rose by 37.48% to ¥2,058,719,211.34, with an increase of ¥56,123.54 million from the previous year[13] - The total assets at the end of Q3 2023 were ¥22,476,012,563.70, an increase of 9.68% from the end of the previous year[4] - The cash flow from operating activities generated a net amount of CNY 2,029,402,975.72, compared to CNY 1,395,070,031.14 in the previous year, indicating a significant increase of 45.4%[29] - The cash and cash equivalents at the end of Q3 2023 amounted to CNY 2,022,842,617.58, an increase from CNY 1,691,911,763.98 at the end of Q3 2022[30] Expenses and Liabilities - Total operating costs amounted to ¥7,354,768,450.44, up from ¥6,289,455,335.33, reflecting a year-over-year increase of 16.9%[26] - The total liabilities increased to ¥9,749,326,551.15 from ¥9,652,689,512.90, reflecting a rise of 1.0%[25] - The company's total operating expenses increased to CNY 10,928,665.52, down from CNY 17,687,425.20 in Q3 2022, indicating improved cost management[27] Research and Development - R&D expenses increased by 67.22% to ¥296,764,121.85, reflecting the company's commitment to enhancing R&D capabilities and technical expertise[14] - Research and development expenses increased significantly to ¥296,764,121.85, compared to ¥177,468,493.98, marking a growth of 67.1%[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 66,106[16] - The top 10 shareholders hold a total of 1,020,000,000 shares, representing approximately 61.54% of total shares[16] - HKSCC NOMINEES LIMITED holds 16.87% of shares, amounting to 301,502,038 shares[16] - Shenzhen Xinchengkang Investment Partnership holds 14.63% of shares, totaling 261,427,958 shares[16] - Pharmaron Holdings Limited owns 10.10% of shares, equating to 180,496,500 shares[16] Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance growth[26] - The company continues to expand its integrated pharmaceutical R&D services globally, maintaining a focus on customer-centric strategies[9]